New Lumigan Eye Drop Formulation for Glaucoma From Allergan Approved by FDA
September 1, 2010
Submit Comments
Allergan has announced that the FDA has approved has approved LUMIGAN(R) (bimatoprost ophthalmic solution) 0.01% as a first-line therapy for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Â LUMIGAN(R) 0.01% is an optimized reformulation of LUMIGAN(R) (bimatoprost ophthalmic solution) 0.03%.
The approval followed a study showing that in patients with open-angle glaucoma or ocular hypertension with an average baseline of 23.5 mm Hg, LUMIGAN(R) 0.01% lowered IOP up to 7 mm Hg from baseline, with only one-third the drug exposure of LUMIGAN(R) 0.03%.
Read the full release issued by Allergan.
You might also enjoy...
- Aton Pharma Acquires Marketing Rights to Preservative-Free Timolol Product Line from Merck
- QLT Shows Positive 4 Week Efficacy in Phase II Study for Glaucoma Using Latanoprost Punctal Plug Delivery System
- Does Delaying Drug Treatment of Patients With Ocular Hypertension Increase the Risk of Glaucoma?
- Is Non-Preserved Latanoprost Superior to Xalatan for Treatment of Glaucoma?
- FDA Approves Generic Version of Xalatan® Eye Drops for Glaucoma
Comments
Jump down to form below to submit your own comments
